
Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms. As a result, the benchmark iShares Biotechnology ETF (NASDAQ: IBB) was highly volatile but ended up down by 1.2% in the year leading to January 17, 2025.
Biotech is a high-risk, high-return space though, as a large number of young companies in this industry work to string together enough funding to keep operations going long enough to hopefully see an important new product come to market. When things do come together, it can be a huge boon for investors—blockbuster drug approvals and even positive clinical trial results can sometimes send shares skyrocketing by hundreds of percentage points.